What is ACT Genomics Taiwan?
ACT Genomics Taiwan is a prominent cancer solution provider specializing in precision medicine services across Taiwan, Singapore, Hong Kong, and Japan. The company leverages a multidisciplinary team of experts in tumor biology, cancer genomics, and bioinformatics to deliver comprehensive treatment guidelines for solid tumors. Their services extend to managing relapse, drug resistance, cancer monitoring, risk assessment, and immunotherapy evaluation, aiming to enhance patient outcomes through advanced genomic insights.
How much funding has ACT Genomics Taiwan raised?
ACT Genomics Taiwan has raised a total of $20.5M across 2 funding rounds:
Series A
$8M
Series B
$12.5M
Series A (2015): $8M, investors not publicly disclosed
Series B (2016): $12.5M led by President International Development and UMC Capital
Key Investors in ACT Genomics Taiwan
President International Development
President International Development Corporation (PIDC) is the investment arm of the Uni-President Group, a conglomerate with diverse interests including food manufacturing, retail, and finance. PIDC leads major investment projects, indicating a strategic interest in expanding the Group's business scope.
UMC Capital
UMC Capital is associated with UMC, a leading global semiconductor foundry company that provides IC fabrication services. Their involvement suggests a potential interest in the technological underpinnings or data infrastructure supporting ACT Genomics' precision medicine solutions.
What's next for ACT Genomics Taiwan?
The substantial enterprise-level funding suggests ACT Genomics Taiwan is in a growth phase, likely focusing on expanding its service reach and technological capabilities. This investment will probably fuel further research and development in cancer genomics, potentially leading to new diagnostic tools and therapeutic strategies. The company's strategic expansion into multiple Asian markets indicates a clear ambition to become a leader in the region's rapidly evolving precision oncology landscape.
See full ACT Genomics Taiwan company page
